ICD10

Prostate Cancer

We are using the prostate cancer definition used by the eMERGE program, with a slight modification to the control definition (prostate_cancer_status_emerge_mod_1). You can review the eMERGE documentation for reference, but please follow this document for implementation.
Modifications:
Combine “Control A” and “Control B” groups from the provided schematic figure into a single control group for analysis
Controls should be filtered based on age >= the minimum age of identified cases to the age distributions of cases and controls are comparable within each study

Owner Phenotyping Groups: 
PRIMED Consortium
View Phenotyping Groups: 
PRIMED Consortium
Final

SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria

Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.

Owner Phenotyping Groups: 
eMERGE Northwestern Group
View Phenotyping Groups: 
eMERGE Mayo Group
eMERGE Phenotype WG
Final

Type 2 Diabetes (T2D)

There are two case algorithms provided for T2D. The first (t2d_dprism_ehr_plus_1) is the preferred case algorithm and includes self-reported T2D information collected from survey. The second (t2d_dprism_ehr_1) is an alternative case algorithm that does NOT include self-reported T2D information collected from survey.
We request harmonization based on the preferred algorithm, but if self-reported T2D survey information is not available, the alternative algorithm is acceptable.

Owner Phenotyping Groups: 
PRIMED Consortium
View Phenotyping Groups: 
PRIMED Consortium
Final

Pages